TAC

AgEagle to Showcase Its Drone Innovations at Renowned Milipol Homeland Security Event and Modern Warfare Week

Retrieved on: 
Thursday, November 9, 2023

Events of this stature are invaluable to educating the industry on the competitive differentiation and value propositions of AgEagle’s leading edge UAS solutions.

Key Points: 
  • Events of this stature are invaluable to educating the industry on the competitive differentiation and value propositions of AgEagle’s leading edge UAS solutions.
  • Importantly, they provide the opportunity to shine a spotlight on our latest drone innovations, including our new eBee VISION,” stated Barrett Mooney, AgEagle’s Chairman and CEO.
  • Milipol Paris 2023 is the leading event dedicated to homeland security and safety.
  • This 3.5 lbs drone can be easily carried, deployed in 3 minutes, hand-launched, and operated by a single pilot.

Cisco Enhances Partner Program to Drive Partner Differentiation and Profitability

Retrieved on: 
Wednesday, November 8, 2023

MIAMI BEACH, Fla., Nov. 8, 2023 /PRNewswire/ -- CISCO PARTNER SUMMIT -- Today at Cisco Partner Summit 2023, Cisco (NASDAQ: CSCO) announced new features, enhancements and tools for its extensive partner community. As Cisco invests in creating more business value throughout the entire customer lifecycle, it has initiated a significant evolution of its flagship incentives to reward partners for selling Cisco hardware, software, and as-a-service solutions. To support partners' competitiveness, Cisco is adding up to six new Solution Specializations within the next nine months.

Key Points: 
  • Cisco Partner Incentive to reward partners on all Cisco software, hardware, and services, and drive incremental growth and customer value.
  • MIAMI BEACH, Fla., Nov. 8, 2023 /PRNewswire/ -- CISCO PARTNER SUMMIT -- Today at Cisco Partner Summit 2023 , Cisco (NASDAQ: CSCO) announced new features, enhancements and tools for its extensive partner community.
  • Today at Cisco Partner Summit 2023, Cisco announced new features, enhancements and tools for its partner community.
  • "The Cisco Partner Incentive is the biggest change we've made to partner incentives in more than a decade and is the capstone on the Cisco Partner Program evolution started in 2020," said Marc Surplus, Vice President of Partner Strategy and Programs at Cisco.

TechTAC® Highlights Tubing Anchor that Can Navigate Oil Well Casing Patches

Retrieved on: 
Tuesday, November 7, 2023

This custom-made anchor leverages innovative mechanics and the unique design of the Slimline® to navigate an oil well casing patch or similar anomaly while still being able to fully set below the patch or affected area.

Key Points: 
  • This custom-made anchor leverages innovative mechanics and the unique design of the Slimline® to navigate an oil well casing patch or similar anomaly while still being able to fully set below the patch or affected area.
  • “Oil well casings may need to be patched for a variety of reasons – from corrosion to mechanical damage – and those patches can create unique challenges for tubing anchors,” said Luke Reary, Operations Manager with TechTAC®.
  • However, this approach can limit the effectiveness of the anchor if the casing patch is placed high up within the well.
  • For example, a 5.5” 20 PPF patched casing has a reduced drift of 4.218” compared to 4.653” for an unpatched casing drift.

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

Retrieved on: 
Tuesday, November 7, 2023

Safety and efficacy outcomes for propensity-matched patients with active LN from the Aspreva Lupus Management Study (ALMS) and the AURORA 1 study were assessed at three and six months.

Key Points: 
  • Safety and efficacy outcomes for propensity-matched patients with active LN from the Aspreva Lupus Management Study (ALMS) and the AURORA 1 study were assessed at three and six months.
  • In AURORA 1, patients received LUPKYNIS® 23.7 mg BID in combination with MMF (target dose 2 g/day) and oral glucocorticoids (starting dose of 25 mg/day tapered to 2.5 mg/day by Week 16).
  • The data showed an improved safety profile over the first six months of treatment with LUPKYNIS® in combination with low-dose glucocorticoids and lower-dose MMF without compromising efficacy.
  • Additional data assessed the disposition of cyclosporine (CSA), tacrolimus (TAC), and voclosporin (VCS) in mouse kidneys relative to its systemic drug exposure.

Final Days to Register for the Latest United States Electric Power Industry Seminar: Renewable Energy, ISO Markets, and Power Transactions (New York City, United States - November 14-15, 2023)

Retrieved on: 
Friday, November 3, 2023

DUBLIN, Nov. 3, 2023 /PRNewswire/ -- The "In-Depth Seminar: Today's U.S. Electric Power Industry, Renewable Energy, ISO Markets, and Power Transactions" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 3, 2023 /PRNewswire/ -- The "In-Depth Seminar: Today's U.S. Electric Power Industry, Renewable Energy, ISO Markets, and Power Transactions" training has been added to ResearchAndMarkets.com's offering.
  • If you're seeking a comprehensive understanding of the U.S. electric power industry, including the intricacies of power transactions, this extensive seminar is tailored for you.
  • This program offers a thorough and lucid overview of the U.S. electric power industry's structure, operations, and its current status.
  • Federal vs state regulatory conflicts, and why restructuring today's power industry and the building new power lines is such a complicated task.

CRITEO REPORTS STRONG THIRD QUARTER 2023 RESULTS

Retrieved on: 
Thursday, November 2, 2023

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Criteo S.A. (NASDAQ: CRTO) ("Criteo" or the "Company"), the commerce media company, today announced financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • "We are pleased to report a strong third quarter marked by organic growth acceleration and market share gains in Retail Media.
  • Revenue for Q3 2023 was $469 million, gross profit was $205 million and Contribution ex-TAC was $245 million.
  • Sarah Glickman, Chief Financial Officer, said, "Our third quarter performance demonstrates our strong focus on execution and cost discipline.
  • The above guidance assumes that no additional acquisitions are completed during the fourth quarter of 2023 or the fiscal year ended December 31, 2023.

TransAlta to Acquire Heartland Generation from Energy Capital Partners for $658 million - Expands Capabilities to Meet Demands of Energy Transition

Retrieved on: 
Thursday, November 2, 2023

The purchase price for the acquisition is $390 million, subject to working capital and other adjustments, as well as the assumption of $268 million of low-cost debt.

Key Points: 
  • The purchase price for the acquisition is $390 million, subject to working capital and other adjustments, as well as the assumption of $268 million of low-cost debt.
  • The Agreement provides that economic benefits arising after October 31, 2023 will be to the account of TransAlta.
  • "With this acquisition we are pleased to announce the addition of highly flexible and complementary assets to our Alberta portfolio.
  • We are excited for TransAlta to continue advancing the energy transition and meeting the reliability and electricity needs of Alberta," said Andrew Gilbert, ECP Partner.

Triumvira Immunologics to Present New Clinical and Preclinical Data on its TAC-T Cell Technology at SITC 2023 Annual Meeting

Retrieved on: 
Monday, October 30, 2023

TAC01-HER2 is an innovative cell-based therapy that involves the utilization of genetically modified T cells derived from the patient themselves.

Key Points: 
  • TAC01-HER2 is an innovative cell-based therapy that involves the utilization of genetically modified T cells derived from the patient themselves.
  • These cells express a T-cell Antigen Coupler (TAC) which is designed to specifically recognize HER2 in tumors.
  • In addition to the TAC01-HER2 candidate, the company is investigating TAC-GUCY2C for the treatment of colorectal cancer and TAC01-CLDN18.2 for the treatment of pancreatic ductal adenocarcinoma and gastric cancer.
  • "Our commitment to developing innovative T cell therapeutics that harness the natural biology of T cells is supported by the promising preliminary results from our ongoing Phase I/II study targeting HER2 in solid tumors.

Rapid Urbanization and Rising Internet Use Propel Online Auction Growth: Asia Pacific Emerges as the Fastest-Growing Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023

Rise in Internet Use for Auctions: The internet has revolutionized the auction industry, enabling global access to auctions 24/7, on any device.

Key Points: 
  • Rise in Internet Use for Auctions: The internet has revolutionized the auction industry, enabling global access to auctions 24/7, on any device.
  • Rapid Urbanization: Urbanization trends have led to increased consumer demand for online auctions, particularly in densely populated urban areas.
  • Surging Millennial Population: High-Net-Worth Millennials are becoming significant spenders in the online auction market as they enter their peak earning years.
  • Cloud-based Live Streaming Online Auctions: Online auctions are incorporating cloud-based live streaming to provide an immersive and interactive experience for bidders.

Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

Retrieved on: 
Wednesday, October 18, 2023

Takeda ( TSE:4502/NYSE:TAK ) today announced that, on October 17, 2023 (IST), it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”), for EUR 130 million, resulting in a tax expense reduction of approximately JPY 63 billion for Takeda.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that, on October 17, 2023 (IST), it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”), for EUR 130 million, resulting in a tax expense reduction of approximately JPY 63 billion for Takeda.
  • On November 28, 2018, Shire received a tax assessment from the Irish Revenue for EUR 398 million in relation to the USD 1,635 million break fee Shire received in connection with the terminated offer by AbbVie to acquire Shire in 2014.
  • Takeda appealed this assessment, and in late 2020 a hearing took place before the Irish Tax Appeals Commission (“TAC”).
  • On July 30, 2021, Takeda received a ruling on the matter, with the TAC ruling in favor of Irish Revenue.